T1	Chemical	0 253	Sorafenib , the first agent developed to target BRAF mutant melanoma , is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer , and is currently in clinical trials for thyroid , lung and brain cancer
T2	Disease	254 255	.
R1	isEquivalentTo	Arg1:T2	Arg2:T1
